Osteitis fibrosa cystica is a bone disorder caused by too much parathyroid hormone (PTH) circulating in the body. The excess hormone accelerates bone breakdown, replacing healthy bone tissue with fibrous tissue, cysts, and characteristic lesions called brown tumors. Once a hallmark of advanced hyperparathyroidism, it now occurs in fewer than 2% of people diagnosed with primary hyperparathyroidism in the United States, largely because routine blood tests catch high calcium levels before the disease progresses this far.
How Excess Parathyroid Hormone Damages Bone
Your parathyroid glands, four small glands behind the thyroid, regulate calcium levels in the blood. When they produce too much PTH, the hormone binds to bone-building cells called osteoblasts. This triggers a chain reaction: the osteoblasts release a signaling molecule that activates bone-destroying cells called osteoclasts. At the same time, the body’s natural braking system for bone destruction gets suppressed. The result is runaway bone resorption, where bone tissue is broken down faster than it can be rebuilt.
As bone is resorbed, it doesn’t just disappear. The empty spaces fill with fibrous connective tissue, and fluid-filled cysts form within the weakened bone. Over time, this process hollows out sections of bone and makes them structurally fragile.
What Causes It
Any condition that drives parathyroid hormone levels abnormally high for a prolonged period can lead to osteitis fibrosa cystica. The two main pathways are primary and secondary hyperparathyroidism.
In primary hyperparathyroidism, the parathyroid glands themselves are the problem. A benign tumor (adenoma) on one or more glands is the most common culprit, causing them to overproduce PTH regardless of whether the body needs it. Less often, all four glands enlarge and overproduce hormone simultaneously.
Secondary hyperparathyroidism develops as a response to another condition, most commonly chronic kidney disease. Failing kidneys can’t properly activate vitamin D or clear phosphorus from the blood. Both problems drive calcium levels down, and the parathyroid glands ramp up PTH production to compensate. Without treatment, this persistent overproduction eventually damages bone in the same way a parathyroid tumor does. End-stage kidney disease remains one of the more common settings where osteitis fibrosa cystica still appears today.
Symptoms and How It Feels
Bone pain is the defining symptom. It tends to be deep, aching, and widespread rather than localized to one spot, though certain areas may hurt more depending on where cysts or brown tumors have formed. The weakened bone structure also raises fracture risk, sometimes from forces that wouldn’t normally cause a break.
Because the underlying problem is excess parathyroid hormone and high blood calcium, people often experience symptoms of hypercalcemia alongside the bone pain. These can include fatigue, frequent urination, excessive thirst, nausea, constipation, and difficulty concentrating. Kidney stones are common. Some people notice muscle weakness or joint stiffness. The combination of vague systemic symptoms with progressive bone pain is what typically prompts further investigation.
What Brown Tumors Are
Brown tumors are one of the most distinctive features of this condition, and despite the name, they are not cancerous. They form in areas where bone resorption has been most aggressive. As bone is destroyed, the space fills with a mix of fibrous tissue, giant cells (similar to osteoclasts), and small areas of bleeding. The blood breaks down over time, leaving iron-containing deposits called hemosiderin that stain the tissue a brownish color, which is how the lesions got their name.
Brown tumors occur in roughly 1.5% to 4.5% of people with hyperparathyroidism. They can appear in the jaw, pelvis, ribs, or long bones. On imaging, they look like dark, hollowed-out areas within bone, and they are sometimes misdiagnosed as bone cancer, metastatic tumors, or giant cell tumors before the parathyroid connection is identified.
How It Shows Up on Imaging
X-rays and CT scans reveal several characteristic patterns. The earliest and most reliable sign is subperiosteal bone resorption, a thinning of the outer bone surface that’s often easiest to spot along the finger bones. Other hallmarks include:
- Salt-and-pepper skull: The skull shows a mottled, granular pattern of tiny light and dark spots caused by patchy bone loss throughout the cranial bones.
- Osteolysis of the distal clavicles: The outer ends of the collarbones dissolve away, creating a tapered or eroded appearance.
- Lytic or multilobular cystic changes: Fluid-filled cysts and areas of bone destruction appear as dark holes within affected bones.
- Brown tumors: These show up as well-defined dark lesions that can occur in multiple bones simultaneously.
Because multiple lytic lesions scattered across several bones can mimic metastatic cancer on a CT scan, accurate diagnosis depends on correlating imaging findings with blood work showing elevated PTH and calcium.
Diagnostic Blood Work
The lab profile for osteitis fibrosa cystica is fairly consistent. Blood tests typically show high calcium, elevated parathyroid hormone, and increased alkaline phosphatase, an enzyme that rises when bone turnover is accelerated. Phosphorus levels in the blood tend to be low, since PTH drives the kidneys to excrete more phosphorus. In cases caused by kidney disease, the pattern shifts slightly: calcium may be low or normal rather than elevated, while phosphorus runs high because the kidneys can no longer clear it.
Treatment and Bone Recovery
The primary treatment targets the source of excess parathyroid hormone. For primary hyperparathyroidism, that means surgical removal of the overactive gland or glands (parathyroidectomy). For secondary hyperparathyroidism caused by kidney disease, management focuses on controlling phosphorus levels, supplementing vitamin D, and sometimes using medications that lower PTH production. If medical management fails, surgical removal of the parathyroid glands may still be necessary.
The good news is that bone can recover substantially once PTH levels normalize. According to a case series and literature review published in JBMR Plus, most bone lesions showed partial remineralization within 6 to 12 months after parathyroidectomy, with a median recovery time of about 9 months. Near-complete or complete remineralization occurred in roughly 70% of patients by their last follow-up imaging. Even large or symptomatic lesions showed substantial improvement within months. Full mineralization, when it happens, can take several years.
About 17% of patients in the reviewed cases needed orthopedic surgery for fractures or bones at imminent risk of fracture, but this was separate from the parathyroid surgery itself. Once the hormonal driver is removed, the body’s normal bone-building processes gradually fill in the cysts and lytic areas with new bone tissue.
Why It’s Rare Today
Osteitis fibrosa cystica was once the way most people with primary hyperparathyroidism were diagnosed, because the disease had to progress far enough to cause visible bone damage before anyone noticed. The widespread adoption of routine blood panels that include calcium measurement changed that. Now, elevated calcium is typically caught years before bone disease develops, and hyperparathyroidism is treated while still in its early, often asymptomatic stage. Fewer than 10% of people with primary hyperparathyroidism develop any degree of this bone disease, and most series place the figure below 2%. It remains more common in regions where routine screening is less available, and in the context of advanced chronic kidney disease where secondary hyperparathyroidism can progress despite medical management.